Posted by Chantel Martiromo, research contributed by PubMed
Despite the safety review conducted by the U.S. Food and Drug
Administration in the process of awarding a health claim for the
cholesterol-lowering properties of soy protein, concerns about the possible goitrogenic effects of soybean isoflavones
persist. In a randomized, double blind, placebo-controlled study to
investigate the effect on thyroid function of a daily supplement
containing 90 mg (aglycone weight) of total isoflavones/day
versus placebo in 38 postmenopausal women, 64-83 years old, not on
hormone replacement therapy. Serum thyroid-stimulating hormone (TSH),
thyroxine (T4), and triiodothyronine (T3) were measured at baseline and
after 90 and 180 days, posted in PubMed, found
that in the supplement group, at baseline and 6 months, TSH (micro
U/ml), T4 (nM), and T3 (nM) levels (mean +/- SE) were 3.00 +/- 0.44,
149.00 +/- 5.04, and 1.53 +/- 0.13, respectively, and 3.49 +/- 0.52,
154.52 +/- 2.09, and 1.78 +/- 0.12, respectively. In the control group,
levels at baseline and at 6 months were 3.35 +/- 0.51, 145.39 +/- 6.69,
and 1.55 +/- 0.18, respectively, and 3.63 +/- 0.57, 153.77 +/- 6.64, and
1.75 +/- 0.10, respectively. Intragroup differences for all three
measures were statistically indistinguishable at 6 months, and levels
were similar between the isoflavone supplement and placebo groups at
each measurement. These results indicate that in this group of healthy
iodine-replete subjects, soy isoflavones do not adversely affect thyroid function.
Chinese Secrets to Fatty Liver and Obesity Reversal
For more information and health articles, please visit women's health http://thetruestoriesstories.blogspot.ca/
No comments:
Post a Comment